What diseases and symptoms are included in the indications of Enzalutamide/Enzalutamide (Anchortan)?

Enzalutamide/Enzalutamide ( Enzalutamide) is a new oral androgen receptor signaling pathway inhibitor and one of the most widely used targeted hormone drugs in the treatment of prostate cancer today. It blocks the stimulating effect of androgens on prostate cancer cells through multiple mechanisms, thereby inhibiting tumor growth and metastasis. Different from traditional androgen deprivation therapy, enzalutamide not only inhibits the production of androgens in the body, but also directly blocks the binding of androgens to receptors and prevents receptors from entering the nucleus. This mechanism makes its therapeutic effect more durable and precise.

In terms of indications, enzalutamide is mainly used to treat patients with advanced or metastatic castration-resistant prostate cancer (mCRPC). Such patients still experience disease progression after receiving androgen castration therapy, which is the most difficult stage in prostate cancer treatment. The emergence of enzalutamide has changed this treatment landscape, allowing many patients to delay tumor growth and significantly improve quality of life after disease progression. In addition, the drug is also suitable for patients with castration-sensitive metastatic prostate cancer (mHSPC), that is, it can be used in combination during the initial treatment phase to achieve better long-term disease control.

In recent years, the research scope of enzalutamide has gradually expanded. The latest clinical practice has found that it also shows potential in high-risk locally advanced prostate cancer and postoperative adjuvant treatment, especially for patients whose PSA continues to rise or who are prone to recurrence. Some overseas research institutions are exploring its combined application with drugs such as abiraterone and dutasteride to form a multi-level androgen suppression strategy.

In addition to its clear indications for prostate cancer, enzalutamide also has an auxiliary effect in relieving bone pain, urinary tract obstruction, fatigue and other symptoms caused by tumors. Because it can significantly reduce tumor activity, thereby improving the risk of skeletal events in patients with bone metastases, patients can obtain longer progression-free survival during treatment.

Reference materials:https://www.xtandi.com/